Dedicated to the development and commercialization of a unique biopolymers platform

Gecko Biomedical is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and commercialization of a unique biopolymer platform to address various unmet clinical needs.

The company’s platform is based on a proprietary polymer family with unique properties including superior biocompatibility, tunable bioresorbability, and adjustable tissue adherence. Furthermore, the polymer hydrophobicity, high viscosity and controlled “on demand” curing enables a unique and controlled delivery to targeted tissues or the creation of scaffolds.

Gecko’s first product, SETALUMTM Sealant, is an innovative polymer for tissue reconstruction, targeting vascular reconstruction as an initial indication. Its structure is tunable, allowing customization for various applications and tissue types. The polymer is part of a biopolymer platform family that is fully industrialized and highly versatile, with potential novel applications in other fields of tissue reconstruction such as guided tissue repair, and the field of localized drug delivery.

The Company’s technology is based on world-class research and intellectual property from the laboratories of Pr Robert Langer (MIT) and Pr Jeff Karp (Brigham and Women’s Hospital), who co-founded the company in 2013, alongside Christophe Bancel and Bernard Gilly from the iBionext Network.



Board of Directors

Scientific advisors


Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China.

Bpifrance, a subsidiary of the Caisse des Dépôts and the French State, a trusted partner for entrepreneurs, supports companies from start-up to their listing on the stock market, through credit, guarantees and equity.

CM-CIC Capital Innovation is specialized in investment and support for high-potential growth companies, with strong technology expertise, in the first stages of their development. It finances firms positioned on sectors such as life sciences, and industrial innovations or environment.

Omnes Capital is a major player in private equity, with a commitment to financing SMEs. With €1.9 billion in assets under management, Omnes Capital provides companies with the capital needed to finance their growth. Omnes Capital, was a subsidiary of Crédit Agricole until it March 2012.

CapDecisif Management is a management company investing in high-potential innovative companies in the sectors of information and communication technology, life sciences, energy and the environment, mainly in the Paris region. Its team was brought together in 2001 and has remained intact since.